Goldman Sachs has downgraded Doximity Inc (DOCS) to a Sell rating from Neutral, effective September 30, 2025. The stock is currently priced at $49.33. This move underscores caution regarding Doximity's outlook, potentially reflecting concerns over competitive pressures and market conditions that may impact the company's performance.
Doximity, based in San Francisco, operates an online platform for medical professionals, offering marketing, hiring, and workflow solutions. As of November 8, 2025, the company holds a market capitalization of $10.2 billion, with a price-to-earnings ratio of 43.25 and an earnings per share of 1.16.
Upcoming earnings reports are scheduled for May 13, 2026, and August 5, 2026, with estimated EPS of $0.33 and $0.38, respectively. Doximity has shown strong recent performance, with Q2 2026 EPS reported at $0.45, exceeding estimates by 16.4%. Analyst consensus remains a Buy, with 8 Strong Buy, 8 Buy, 8 Hold, and 2 Sell ratings among 26 analysts as of November 1, 2025.